SK5242003A3 - Human cord blood derived unrestricted somatic stem cells (USSC) - Google Patents

Human cord blood derived unrestricted somatic stem cells (USSC) Download PDF

Info

Publication number: SK5242003A3
Authority: SK; Slovakia
Prior art keywords: cells; stem cells; somatic stem; ussc; cell
Prior art date: 2000-11-03

Application number

SK524-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Peter Wernet

Original Assignee

Kourion Therapeutics Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-11-03

Filing date

2001-11-03

Publication date

2003-11-04

2001-11-03 Application filed by Kourion Therapeutics Gmbh filed Critical Kourion Therapeutics Gmbh

2003-11-04 Publication of SK5242003A3 publication Critical patent/SK5242003A3/sk

Links

210000001988 somatic stem cell Anatomy 0.000 title claims abstract description 34
210000004700 fetal blood Anatomy 0.000 title claims abstract description 29
210000004027 cell Anatomy 0.000 claims abstract description 109
210000000130 stem cell Anatomy 0.000 claims abstract description 46
210000000988 bone and bone Anatomy 0.000 claims abstract description 20
230000001537 neural effect Effects 0.000 claims abstract description 15
238000000338 in vitro Methods 0.000 claims abstract description 13
239000000203 mixture Substances 0.000 claims abstract description 9
239000003814 drug Substances 0.000 claims abstract description 7
210000004369 blood Anatomy 0.000 claims abstract description 6
239000008280 blood Substances 0.000 claims abstract description 6
230000003169 placental effect Effects 0.000 claims abstract description 5
210000002901 mesenchymal stem cell Anatomy 0.000 claims description 18
239000000427 antigen Substances 0.000 claims description 14
102000036639 antigens Human genes 0.000 claims description 14
108091007433 antigens Proteins 0.000 claims description 14
230000014509 gene expression Effects 0.000 claims description 14
239000003550 marker Substances 0.000 claims description 14
238000000034 method Methods 0.000 claims description 12
108090000623 proteins and genes Proteins 0.000 claims description 12
210000001519 tissue Anatomy 0.000 claims description 12
230000001464 adherent effect Effects 0.000 claims description 11
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 9
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 9
230000003394 haemopoietic effect Effects 0.000 claims description 9
238000002955 isolation Methods 0.000 claims description 8
108010034065 fibulin 2 Proteins 0.000 claims description 7
210000001178 neural stem cell Anatomy 0.000 claims description 7
102100031813 Fibulin-2 Human genes 0.000 claims description 6
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 6
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 6
238000004458 analytical method Methods 0.000 claims description 6
210000003958 hematopoietic stem cell Anatomy 0.000 claims description 6
230000012010 growth Effects 0.000 claims description 5
239000003102 growth factor Substances 0.000 claims description 5
108010013996 Fibromodulin Proteins 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
210000000056 organ Anatomy 0.000 claims description 4
238000012360 testing method Methods 0.000 claims description 4
102100022749 Aminopeptidase N Human genes 0.000 claims description 3
102000017177 Fibromodulin Human genes 0.000 claims description 3
101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims description 3
101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 claims description 3
108090000320 Hyaluronan Synthases Proteins 0.000 claims description 3
102100025304 Integrin beta-1 Human genes 0.000 claims description 3
108091023040 Transcription factor Proteins 0.000 claims description 3
102000040945 Transcription factor Human genes 0.000 claims description 3
239000012620 biological material Substances 0.000 claims description 3
210000004204 blood vessel Anatomy 0.000 claims description 3
239000002771 cell marker Substances 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
102100032912 CD44 antigen Human genes 0.000 claims description 2
101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
102000003918 Hyaluronan Synthases Human genes 0.000 claims description 2
238000004115 adherent culture Methods 0.000 claims description 2
210000001671 embryonic stem cell Anatomy 0.000 claims description 2
230000003511 endothelial effect Effects 0.000 claims description 2
238000001415 gene therapy Methods 0.000 claims description 2
210000002460 smooth muscle Anatomy 0.000 claims description 2
230000002792 vascular Effects 0.000 claims description 2
208000019553 vascular disease Diseases 0.000 claims description 2
208000020084 Bone disease Diseases 0.000 claims 1
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
208000019622 heart disease Diseases 0.000 claims 1
208000019423 liver disease Diseases 0.000 claims 1
210000005155 neural progenitor cell Anatomy 0.000 claims 1
230000000399 orthopedic effect Effects 0.000 claims 1
230000004069 differentiation Effects 0.000 abstract description 19
230000006698 induction Effects 0.000 abstract description 12
230000001172 regenerating effect Effects 0.000 abstract description 8
210000000845 cartilage Anatomy 0.000 abstract description 7
210000003205 muscle Anatomy 0.000 abstract description 5
230000011132 hemopoiesis Effects 0.000 abstract description 4
230000000977 initiatory effect Effects 0.000 abstract description 3
229940079593 drug Drugs 0.000 abstract 1
238000012423 maintenance Methods 0.000 abstract 1
238000010186 staining Methods 0.000 description 23
239000002609 medium Substances 0.000 description 18
210000005087 mononuclear cell Anatomy 0.000 description 17
210000004185 liver Anatomy 0.000 description 14
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 12
229960003957 dexamethasone Drugs 0.000 description 12
238000002360 preparation method Methods 0.000 description 11
102000000503 Collagen Type II Human genes 0.000 description 10
108010041390 Collagen Type II Proteins 0.000 description 10
230000009816 chondrogenic differentiation Effects 0.000 description 9
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 8
230000009818 osteogenic differentiation Effects 0.000 description 8
238000002054 transplantation Methods 0.000 description 8
239000002953 phosphate buffered saline Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 6
102000001301 EGF receptor Human genes 0.000 description 6
108060006698 EGF receptor Proteins 0.000 description 6
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
102000053171 Glial Fibrillary Acidic Human genes 0.000 description 6
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 6
102000004067 Osteocalcin Human genes 0.000 description 6
108090000573 Osteocalcin Proteins 0.000 description 6
108010067787 Proteoglycans Proteins 0.000 description 6
102000016611 Proteoglycans Human genes 0.000 description 6
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
239000013615 primer Substances 0.000 description 6
238000003757 reverse transcription PCR Methods 0.000 description 6
102000002260 Alkaline Phosphatase Human genes 0.000 description 5
108020004774 Alkaline Phosphatase Proteins 0.000 description 5
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
102000006354 HLA-DR Antigens Human genes 0.000 description 5
108010058597 HLA-DR Antigens Proteins 0.000 description 5
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 5
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 5
210000001789 adipocyte Anatomy 0.000 description 5
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
230000001605 fetal effect Effects 0.000 description 5
239000008103 glucose Substances 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
229930002330 retinoic acid Natural products 0.000 description 5
102000007469 Actins Human genes 0.000 description 4
108010085238 Actins Proteins 0.000 description 4
102100032925 Chondroadherin Human genes 0.000 description 4
102000012422 Collagen Type I Human genes 0.000 description 4
108010022452 Collagen Type I Proteins 0.000 description 4
108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 4
102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 4
102000003505 Myosin Human genes 0.000 description 4
108060008487 Myosin Proteins 0.000 description 4
102000008730 Nestin Human genes 0.000 description 4
108010088225 Nestin Proteins 0.000 description 4
102000008763 Neurofilament Proteins Human genes 0.000 description 4
108010088373 Neurofilament Proteins Proteins 0.000 description 4
102000004874 Synaptophysin Human genes 0.000 description 4
108090001076 Synaptophysin Proteins 0.000 description 4
229960005070 ascorbic acid Drugs 0.000 description 4
235000010323 ascorbic acid Nutrition 0.000 description 4
239000011668 ascorbic acid Substances 0.000 description 4
DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 4
GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
108010059427 chondroadherin Proteins 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
238000000799 fluorescence microscopy Methods 0.000 description 4
230000002518 glial effect Effects 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
230000010354 integration Effects 0.000 description 4
210000005228 liver tissue Anatomy 0.000 description 4
210000005055 nestin Anatomy 0.000 description 4
210000005044 neurofilament Anatomy 0.000 description 4
230000002188 osteogenic effect Effects 0.000 description 4
101710135378 pH 6 antigen Proteins 0.000 description 4
239000013641 positive control Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
229960001727 tretinoin Drugs 0.000 description 4
108010081589 Becaplermin Proteins 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
238000012752 Hepatectomy Methods 0.000 description 3
102100037852 Insulin-like growth factor I Human genes 0.000 description 3
108010025020 Nerve Growth Factor Proteins 0.000 description 3
102000015336 Nerve Growth Factor Human genes 0.000 description 3
102000004264 Osteopontin Human genes 0.000 description 3
108010081689 Osteopontin Proteins 0.000 description 3
102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
238000010240 RT-PCR analysis Methods 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000002648 chondrogenic effect Effects 0.000 description 3
238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
229960003692 gamma aminobutyric acid Drugs 0.000 description 3
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
238000012744 immunostaining Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
210000003061 neural cell Anatomy 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 2
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
GEBBCNXOYOVGQS-BNHYGAARSA-N 4-amino-1-[(2r,3r,4s,5s)-3,4-dihydroxy-5-(hydroxyamino)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](NO)O1 GEBBCNXOYOVGQS-BNHYGAARSA-N 0.000 description 2
102100032528 C-type lectin domain family 11 member A Human genes 0.000 description 2
101710167766 C-type lectin domain family 11 member A Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
102000002664 Core Binding Factor Alpha 2 Subunit Human genes 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
102100037362 Fibronectin Human genes 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 2
101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 description 2
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
102100032817 Integrin alpha-5 Human genes 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
108010013709 Leukocyte Common Antigens Proteins 0.000 description 2
102000017095 Leukocyte Common Antigens Human genes 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000008109 Mixed Function Oxygenases Human genes 0.000 description 2
108010074633 Mixed Function Oxygenases Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 2
108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
238000011579 SCID mouse model Methods 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000009815 adipogenic differentiation Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
210000002960 bfu-e Anatomy 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
210000002449 bone cell Anatomy 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
210000004271 bone marrow stromal cell Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000003321 cartilage cell Anatomy 0.000 description 2
230000022159 cartilage development Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
210000001612 chondrocyte Anatomy 0.000 description 2
230000005757 colony formation Effects 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000008021 deposition Effects 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000002744 extracellular matrix Anatomy 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000004761 fibrosis Effects 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000006481 glucose medium Substances 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
238000007689 inspection Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
210000005229 liver cell Anatomy 0.000 description 2
230000004807 localization Effects 0.000 description 2
238000002826 magnetic-activated cell sorting Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000001000 micrograph Methods 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
239000011707 mineral Substances 0.000 description 2
210000000651 myofibroblast Anatomy 0.000 description 2
210000004498 neuroglial cell Anatomy 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
210000000963 osteoblast Anatomy 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
101150002954 rmf gene Proteins 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
101800000263 Acidic protein Proteins 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
101150082143 CD24 gene Proteins 0.000 description 1
102000013925 CD34 antigen Human genes 0.000 description 1
108050003733 CD34 antigen Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000189662 Calla Species 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
206010019663 Hepatic failure Diseases 0.000 description 1
108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 1
108050004132 Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
102100036721 Insulin receptor Human genes 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
108090000143 Mouse Proteins Proteins 0.000 description 1
101100437777 Mus musculus Bmpr1a gene Proteins 0.000 description 1
101100481410 Mus musculus Tek gene Proteins 0.000 description 1
102000003729 Neprilysin Human genes 0.000 description 1
108090000028 Neprilysin Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 1
108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
102100038081 Signal transducer CD24 Human genes 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000003367 anti-collagen effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
210000001188 articular cartilage Anatomy 0.000 description 1
229960002756 azacitidine Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000033558 biomineral tissue development Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000009640 blood culture Methods 0.000 description 1
230000010478 bone regeneration Effects 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
238000009933 burial Methods 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000010367 cloning Methods 0.000 description 1
229940096422 collagen type i Drugs 0.000 description 1
238000012136 culture method Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
101150022753 galc gene Proteins 0.000 description 1
239000011521 glass Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229940116978 human epidermal growth factor Drugs 0.000 description 1
229940099552 hyaluronan Drugs 0.000 description 1
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000013394 immunophenotyping Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000016507 interphase Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
208000007903 liver failure Diseases 0.000 description 1
231100000835 liver failure Toxicity 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
238000002493 microarray Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000004070 myogenic differentiation Effects 0.000 description 1
GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
230000011164 ossification Effects 0.000 description 1
230000001582 osteoblastic effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
229960002429 proline Drugs 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
230000037387 scars Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
210000003594 spinal ganglia Anatomy 0.000 description 1
210000004500 stellate cell Anatomy 0.000 description 1
238000009168 stem cell therapy Methods 0.000 description 1
238000009580 stem-cell therapy Methods 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000036266 weeks of gestation Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Developmental Biology & Embryology (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Immunology (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
Neurology (AREA)
Hematology (AREA)
Diabetes (AREA)
Wood Science & Technology (AREA)
Neurosurgery (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)

SK524-2003A 2000-11-03 2001-11-03 Human cord blood derived unrestricted somatic stem cells (USSC) SK5242003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US24516800P	2000-11-03	2000-11-03
PCT/EP2001/012768 WO2002036751A2 (en)	2000-11-03	2001-11-03	Human cord blood derived unrestricted somatic stem cells (ussc)

Publications (1)

Publication Number	Publication Date
SK5242003A3 true SK5242003A3 (en)	2003-11-04

Family

ID=22925565

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK524-2003A SK5242003A3 (en)	2000-11-03	2001-11-03	Human cord blood derived unrestricted somatic stem cells (USSC)

Country Status (25)

Country	Link
US (3)	US7560280B2 (no)
EP (1)	EP1404815B1 (no)
JP (2)	JP4799804B2 (no)
CN (1)	CN100480375C (no)
AT (1)	ATE340255T1 (no)
AU (2)	AU2002229533B2 (no)
BG (1)	BG107770A (no)
CA (1)	CA2426987C (no)
CY (1)	CY1106287T1 (no)
CZ (1)	CZ20031165A3 (no)
DE (1)	DE60123293T2 (no)
DK (1)	DK1404815T3 (no)
EA (1)	EA008619B1 (no)
EE (1)	EE200300205A (no)
ES (1)	ES2272563T3 (no)
HK (1)	HK1071771A1 (no)
HU (1)	HUP0301600A3 (no)
IL (2)	IL155608A0 (no)
MX (1)	MXPA03003844A (no)
NO (1)	NO20031999L (no)
PL (1)	PL362293A1 (no)
PT (1)	PT1404815E (no)
SK (1)	SK5242003A3 (no)
UA (1)	UA81390C2 (no)
WO (1)	WO2002036751A2 (no)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1100529B2 (en) *	1998-07-30	2010-08-25	The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health	Thymosin beta 4 promotes wound repair
US8609412B2 (en) *	1999-08-05	2013-12-17	Regents Of The University Of Minnesota	Mapc generation of lung tissue
US7015037B1 (en) *	1999-08-05	2006-03-21	Regents Of The University Of Minnesota	Multiponent adult stem cells and methods for isolation
WO2005056026A1 (en)	2003-12-04	2005-06-23	Regents Of The University Of Minnesota	Compositions and methods for the treatment of lysosomal storage disorders
US10638734B2 (en)	2004-01-05	2020-05-05	Abt Holding Company	Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US8252280B1 (en)	1999-08-05	2012-08-28	Regents Of The University Of Minnesota	MAPC generation of muscle
US7927587B2 (en) *	1999-08-05	2011-04-19	Regents Of The University Of Minnesota	MAPC administration for the treatment of lysosomal storage disorders
US8075881B2 (en) *	1999-08-05	2011-12-13	Regents Of The University Of Minnesota	Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
EP1226233B1 (en) *	1999-08-05	2011-06-29	ABT Holding Company	Multipotent adult stem cells and methods for isolation
CA2438501C (en) *	2001-02-14	2014-09-16	Leo T. Furcht	Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
CN1547480A (zh) *	2001-08-29	2004-11-17	雷根内克斯生物制药有限公司	用胸腺素β4、类似物、同型物和其他衍生物在心肌事件发生前、过程中或刚发生后治疗或预防炎症、损伤和其他改变的方法
DE10144326B4 (de) *	2001-09-10	2005-09-22	Siemens Ag	Verfahren und System zur Überwachung eines Reifenluftdrucks
DE10158680B4 (de) *	2001-11-30	2004-04-08	Universitätsklinikum Hamburg-Eppendorf	Verfahren zur ex vivo-Expansion und -Differenzierung von multipotenten Stammzellen
CA2473749C (en) *	2002-01-23	2012-05-22	University Of Utah Research Foundation	Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof
JP2005517441A (ja) *	2002-02-19	2005-06-16	メディポスト・カンパニー・リミテッド	臍帯血由来の間葉幹細胞・前駆細胞の分離培養方法及び間葉組織への分化誘導方法
JP2006509770A (ja)	2002-11-26	2006-03-23	アンソロジェネシスコーポレーション	細胞治療学、細胞治療単位、およびそれらを利用した治療法
WO2004050859A2 (en)	2002-11-27	2004-06-17	Regents Of The University Of Minnesota	Homologous recombination in multipotent adult progenitor cells
US7470538B2 (en) *	2002-12-05	2008-12-30	Case Western Reserve University	Cell-based therapies for ischemia
WO2004052177A2 (en) *	2002-12-05	2004-06-24	Case Western Reserve University	Cell-based therapies for ischemia
JP3762975B2 (ja) *	2003-03-18	2006-04-05	学校法人慶應義塾	単球由来多能性細胞ｍｏｍｃ
US20040203142A1 (en) *	2003-04-14	2004-10-14	Reliance Life Sciences Pvt. Ltd.	Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation thereof for therapeutic purposes
JP4950661B2 (ja)	2003-06-27	2012-06-13	エチコン、インコーポレイテッド	分娩後由来細胞類を使用する、神経組織の再生および修復
US8790637B2 (en)	2003-06-27	2014-07-29	DePuy Synthes Products, LLC	Repair and regeneration of ocular tissue using postpartum-derived cells
AU2003304250A1 (en)	2003-06-27	2005-01-13	Universite Laval	Method of isolating cells from umbilical cord
WO2005032251A1 (en) *	2003-10-09	2005-04-14	I.M.T. Interface Multigrad Technology Ltd.	Method for freezing, thawing and transplantation of viable cartilage
GB0329449D0 (en) *	2003-12-19	2004-01-28	Omnicyte Ltd	Stem cells
JP2007520462A (ja) *	2003-12-19	2007-07-26	バイアセルインコーポレーティッド	ヒト臍帯血由来多能性細胞の疾患の処置のための使用方法
EP1544290A1 (en) *	2003-12-19	2005-06-22	Yu-Show Fu	A cell system for generating somatic cells
JP4777908B2 (ja) *	2004-02-02	2011-09-21	コア・ダイナミクス・リミテッド	生物学的材料ならびに生物学的材料の保存のための方法および溶液
WO2005073652A2 (en) *	2004-02-02	2005-08-11	I.M.T. Interface Multigrad Technology Ltd.	Apparatus, system and method for lyophilization
EP1718735A1 (en) *	2004-02-11	2006-11-08	Aldagen, Inc.	Stem cell populations and methods of use
EP1747265B1 (en) *	2004-04-23	2011-04-20	BioE LLC	Multi-lineage progenitor cells
US7622108B2 (en)	2004-04-23	2009-11-24	Bioe, Inc.	Multi-lineage progenitor cells
US20070298015A1 (en) *	2004-04-28	2007-12-27	Viacell, Inc.	Treatment of Muscular Dystrophy with Mobilized Peripheral Blood Pluripotent Cells
JP2007536935A (ja)	2004-05-14	2007-12-20	ベクトン・ディキンソン・アンド・カンパニー	間葉幹細胞の無血清増殖のための細胞培養環境
EP1753472B1 (en) *	2004-06-07	2010-03-17	Core Dynamics Ltd	Method for sterilization of biological preparations
EP1778007A1 (en) *	2004-08-12	2007-05-02	I.M.T. Interface Multigrad Technology Ltd.	Method and apparatus for freezing or thawing of a biological material
US9056093B2 (en)	2005-01-07	2015-06-16	Wake Forest University Health Sciences	Regeneration of pancreatic islets by amniotic fluid stem cell therapy
EP2428563A1 (en) *	2005-02-10	2012-03-14	Regents Of The University Of Minnesota	Vascular/lymphatic endothelial cells
EP1850661A2 (en) *	2005-02-22	2007-11-07	Interface Multigrad Technology (IMT) Ltd.	Preserved viable cartilage, method for its preservation, and system and devices used therefor
CN101575590B (zh) *	2005-02-28	2012-05-23	中国医学科学院血液学研究所泰达生命科学技术研究中心	人脐带间充质干细胞的制备方法
EP1874922A4 (en) *	2005-04-19	2009-10-28	Univ Johns Hopkins	METHOD USING STROMA CELLS FROM UMBILICAL CORD BLOOD TO DEVELOP AND GRAFT NUCLEAR CELLS DERIVED FROM UMBILICAL CORD BLOOD
WO2006121454A2 (en) *	2005-05-05	2006-11-16	Regents Of The University Of Minnesota	Use of mapc or progeny therefrom to populate lymphohematopoietic tissues
CN101218341A (zh) *	2005-05-05	2008-07-09	明尼苏达大学董事会	Nk细胞抑制作用用于促进定植的mhc-i阴性细胞持续存在的用途
EP2662439A1 (en) *	2005-05-27	2013-11-13	Viacord, LLC	Treatment of ischemia using stem cells
US20080194024A1 (en) *	2005-07-29	2008-08-14	Mays Robert W	Culture of Non-Embryonic Cells at High Cell Density
EP1909565A2 (en)	2005-08-03	2008-04-16	Interface Multigrad Technology (IMT) Ltd.	Somatic cells for use in cell therapy
DE602005017812D1 (de) *	2005-08-26	2009-12-31	Seoul Nat Univ Ind Foundation	Multipotente blutstammzellen aus der nabelschnur und zellbehandlungsmittel damit zur behandlung der ischämischen krankheit
EP1941032A2 (en)	2005-10-14	2008-07-09	Regents Of The University Of Minnesota	Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype
ES2642844T3 (es)	2005-12-16	2017-11-20	DePuy Synthes Products, Inc.	Composiciones y métodos para inhibir una respuesta inmune adversa en el trasplante de histocompatibilidad que no coinciden
US9125906B2 (en)	2005-12-28	2015-09-08	DePuy Synthes Products, Inc.	Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
PL2471903T3 (pl)	2005-12-29	2018-09-28	Anthrogenesis Corporation	Populacje komórek macierzystych łożyska
WO2007121443A2 (en) *	2006-04-17	2007-10-25	Bioe, Inc.	Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
US7875453B2 (en) *	2006-06-14	2011-01-25	Bioe Llc	Differentiation of multi-lineage progenitor cells to hepatocytes
ES2524443T3 (es) *	2006-11-13	2014-12-09	DePuy Synthes Products, LLC	Expansión in vitro de células postparto usando microportadores
WO2008085229A2 (en) *	2006-11-15	2008-07-17	Arteriocyte Inc.	Cell-based therapies for treating liver disease
EP2087101A2 (en) *	2006-11-24	2009-08-12	Regents of the University of Minnesota	Endodermal progenitor cells
AU2007326171B2 (en)	2006-11-30	2012-11-15	Medipost Co., Ltd.	Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells
US20090029463A1 (en) *	2007-07-25	2009-01-29	Bioe, Inc.	Differentiation of Multi-Lineage Progenitor Cells to Chondrocytes
MX2010004914A (es) *	2007-10-31	2010-08-18	Cryo Cell Int	Metodos para cocultivar celulas derivadas de sangre de cordon umbilical con celulas madre menstruales.
US20120156134A1 (en)	2007-12-20	2012-06-21	Shayne Squires	Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
CN101978047A (zh)	2008-01-18	2011-02-16	明尼苏达大学董事会	干细胞聚集体及制备和使用方法
US20090202978A1 (en) *	2008-02-13	2009-08-13	Ginadi Shaham	Method and apparatus for freezing of a biological material
US20090233993A1 (en) *	2008-03-06	2009-09-17	Burnham Institute For Medical Research	Compositions and methods for inhibiting gsk3 activity and uses thereof
CN101543644B (zh) *	2008-03-27	2012-07-25	中国人民解放军总医院	无支架工程软骨组织的构建方法及其产品
CA2724839A1 (en) *	2008-05-21	2009-11-26	Bioe Llc	Differentiation of multi-lineage progenitor cells to pancreatic cells
JP2012500792A (ja)	2008-08-22	2012-01-12	アンスロジェネシスコーポレーション	胎盤細胞集団による骨欠損の治療のための方法および組成物
EP4032552B1 (en)	2008-08-26	2023-10-04	City of Hope	Method and compositions for enhanced anti-tumor effector functioning of t cells
GB0818725D0 (en)	2008-10-13	2008-11-19	Habib Nagy A	Pharmaceutical composition
EP2182055A1 (en)	2008-10-14	2010-05-05	Heinrich-Heine-Universität Düsseldorf	Human cord blood derived unrestricted somatic stem cells (USSC)
WO2010049752A1 (en)	2008-10-31	2010-05-06	Katholieke Universiteit Leuven	Optimized methods for differentiation of cells into cells with hepatocyte and hepatocyte progenitor phenotypes, cells produced by the methods, and methods for using the cells
KR20100054711A (ko)	2008-11-14	2010-05-25	메디포스트(주)	간엽 줄기세포 또는 이의 배양액을 포함하는 신경질환의 예방 또는 치료용 조성물
US10179900B2 (en)	2008-12-19	2019-01-15	DePuy Synthes Products, Inc.	Conditioned media and methods of making a conditioned media
AU2010276264B2 (en)	2009-07-21	2013-09-19	Abt Holding Company	Use of stem cells to reduce leukocyte extravasation
EP2456853B1 (en)	2009-07-21	2020-10-28	ABT Holding Company	Use of stem cells to reduce leukocyte extravasation
US9081008B2 (en)	2009-12-04	2015-07-14	James Sherley	Detecting and counting tissue—specific stem cells and uses thereof
US8759098B2 (en)	2009-12-04	2014-06-24	Boston Biomedical Research Institute, Inc.	Method for cloning pluripotent stem cells
WO2011106476A1 (en) *	2010-02-25	2011-09-01	Abt Holding Company	Modulation of microglia activation
SG10201914001QA (en)	2010-02-25	2020-03-30	Abt Holding Co	Modulation of macrophage activation
US20110206647A1 (en) *	2010-02-25	2011-08-25	Abt Holding Company	Modulation of Angiogenesis
MX2012011543A (es)	2010-04-08	2013-05-06	Anthrogenesis Corp	Tratamiento de sarcoidosis empleando celulas madre placentarias.
WO2011143415A1 (en)	2010-05-12	2011-11-17	Abt Holding Company	Modulation of splenocytes in cell therapy
US9090878B2 (en)	2010-06-17	2015-07-28	Katholieke Universiteit Leuven	Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
WO2012027358A1 (en)	2010-08-23	2012-03-01	President And Fellows Of Harvard College	Optogenetic probes for measuring membrane potential
CA2809245C (en)	2010-08-24	2020-07-14	Regents Of The University Of Minnesota	Non-static suspension culture of cell aggregates
US9725689B2 (en)	2010-10-08	2017-08-08	Terumo Bct, Inc.	Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
AU2011352036A1 (en)	2010-12-31	2013-07-18	Anthrogenesis Corporation	Enhancement of placental stem cell potency using modulatory RNA molecules
US20120258439A1 (en) *	2011-04-11	2012-10-11	Ali Bin M Abdullah Jaffar	Protein-Free Culture Media Products
CN102776150A (zh) *	2011-05-13	2012-11-14	上海交通大学医学院附属第九人民医院	一种诱导脐带间充质干细胞分化为内皮细胞的方法
US9040035B2 (en)	2011-06-01	2015-05-26	Anthrogenesis Corporation	Treatment of pain using placental stem cells
HUE047474T2 (hu)	2011-06-06	2020-04-28	ReGenesys BVBA	Õssejtek expanziója üreges rostbioreaktorokban
GB201119335D0 (en)	2011-11-09	2011-12-21	Univ Leuven Kath	Hepatitis virus infectable stem cells
SG11201508403XA (en)	2013-04-12	2015-11-27	Saverio Lafrancesca	Improving organs for transplantation
EP2992088B1 (en)	2013-04-30	2019-08-21	Katholieke Universiteit Leuven	Cell therapy for myelodysplastic syndromes
WO2015073913A1 (en)	2013-11-16	2015-05-21	Terumo Bct, Inc.	Expanding cells in a bioreactor
EP2952578A1 (de)	2014-06-03	2015-12-09	Peter Wernet	Epigenetische Reprogrammierung von fötalen Stammzellen
JP6657195B2 (ja)	2014-09-19	2020-03-04	シティ・オブ・ホープＣｉｔｙｏｆＨｏｐｅ	Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞
TW201613622A (en) *	2014-10-14	2016-04-16	Bionet Corp	Composition for skincare and pharmaceutical composition and preparation method thereof
AU2016387339B2 (en)	2016-01-21	2022-11-17	Abt Holding Company	Stem cells for wound healing
CN106377547B (zh) *	2016-09-30	2019-05-31	孔五一	脐带血再生粒子的提取方法及其用途
CN113637633B (zh) *	2021-08-16	2023-11-03	浙江大学	一种促进间充质干细胞向成骨细胞分化的方法
CA3232099A1 (en)	2021-09-23	2023-03-30	Adam Ezra Cohen	Genetically encoded voltage indicators and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3639949A1 (de)	1986-11-22	1988-06-09	Diagen Inst Molekularbio	Verfahren zur trennung von langkettigen nukleinsaeuren
US5192553A (en) *	1987-11-12	1993-03-09	Biocyte Corporation	Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5486359A (en) *	1990-11-16	1996-01-23	Osiris Therapeutics, Inc.	Human mesenchymal stem cells
US5851832A (en) *	1991-07-08	1998-12-22	Neurospheres, Ltd.	In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5672346A (en) *	1992-07-27	1997-09-30	Indiana University Foundation	Human stem cell compositions and methods
US6482231B1 (en) *	1995-11-20	2002-11-19	Giovanni Abatangelo	Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative
US5842477A (en) *	1996-02-21	1998-12-01	Advanced Tissue Sciences, Inc.	Method for repairing cartilage
WO1997039104A1 (en) *	1996-04-17	1997-10-23	Osiris Therapeutics, Inc.	Cryopreservation and extensive subculturing of human mesenchymal stem cells
US5843633A (en) *	1996-04-26	1998-12-01	Amcell Corporation	Characterization of a human hematopoietic progenitor cell antigen
JPH10295369A (ja)	1997-02-26	1998-11-10	Japan Tobacco Inc	造血幹細胞の製造方法
JPH10306027A (ja)	1997-03-07	1998-11-17	Otsuka Pharmaceut Co Ltd	免疫寛容誘導剤
US6387369B1 (en) *	1997-07-14	2002-05-14	Osiris Therapeutics, Inc.	Cardiac muscle regeneration using mesenchymal stem cells
DE19833476B4 (de)	1998-07-24	2005-08-25	Huss, Ralf, Dr.	Genetisch modifizierte CD34-Negative, adhärent wachsende hämatopoetische Stammzellen und deren Verwendung in der Gentherapie
CA2371017A1 (en)	1999-04-27	2000-11-02	Layton Bioscience, Inc.	Cell therapy for chronic stroke
US20020142457A1 (en) *	1999-12-28	2002-10-03	Akihiro Umezawa	Cell having the potentiality of differentiation into cardiomyocytes
JP2005517441A (ja) *	2002-02-19	2005-06-16	メディポスト・カンパニー・リミテッド	臍帯血由来の間葉幹細胞・前駆細胞の分離培養方法及び間葉組織への分化誘導方法
US20040197310A1 (en) *	2003-02-12	2004-10-07	Sanberg Paul R.	Compositions and methods for using umbilical cord progenitor cells in the treatment of myocardial infarction

2001
- 2001-11-02 US US09/985,335 patent/US7560280B2/en not_active Expired - Fee Related
- 2001-11-03 WO PCT/EP2001/012768 patent/WO2002036751A2/en active IP Right Grant
- 2001-11-03 PL PL36229301A patent/PL362293A1/xx unknown
- 2001-11-03 EE EEP200300205A patent/EE200300205A/xx unknown
- 2001-11-03 HU HU0301600A patent/HUP0301600A3/hu unknown
- 2001-11-03 EP EP01990388A patent/EP1404815B1/en not_active Expired - Lifetime
- 2001-11-03 PT PT01990388T patent/PT1404815E/pt unknown
- 2001-11-03 UA UA2003044039A patent/UA81390C2/xx unknown
- 2001-11-03 CN CNB018217028A patent/CN100480375C/zh not_active Expired - Lifetime
- 2001-11-03 JP JP2002539497A patent/JP4799804B2/ja not_active Expired - Lifetime
- 2001-11-03 AT AT01990388T patent/ATE340255T1/de active
- 2001-11-03 ES ES01990388T patent/ES2272563T3/es not_active Expired - Lifetime
- 2001-11-03 AU AU2002229533A patent/AU2002229533B2/en not_active Expired
- 2001-11-03 CA CA2426987A patent/CA2426987C/en not_active Expired - Lifetime
- 2001-11-03 IL IL15560801A patent/IL155608A0/xx unknown
- 2001-11-03 MX MXPA03003844A patent/MXPA03003844A/es active IP Right Grant
- 2001-11-03 EA EA200300536A patent/EA008619B1/ru not_active IP Right Cessation
- 2001-11-03 CZ CZ20031165A patent/CZ20031165A3/cs unknown
- 2001-11-03 AU AU2953302A patent/AU2953302A/xx active Pending
- 2001-11-03 DE DE60123293T patent/DE60123293T2/de not_active Expired - Lifetime
- 2001-11-03 DK DK01990388T patent/DK1404815T3/da active
- 2001-11-03 SK SK524-2003A patent/SK5242003A3/sk not_active Application Discontinuation
2003
- 2003-04-28 IL IL155608A patent/IL155608A/en not_active IP Right Cessation
- 2003-04-30 BG BG107770A patent/BG107770A/bg unknown
- 2003-05-02 NO NO20031999A patent/NO20031999L/no not_active Application Discontinuation
2004
- 2004-01-15 US US10/758,644 patent/US7556801B2/en not_active Expired - Fee Related
2005
- 2005-05-31 HK HK05104566.1A patent/HK1071771A1/xx not_active IP Right Cessation
2006
- 2006-12-11 CY CY20061101781T patent/CY1106287T1/el unknown
2008
- 2008-01-28 JP JP2008016859A patent/JP4805960B2/ja not_active Expired - Lifetime
2009
- 2009-04-02 US US12/417,294 patent/US20090238803A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EA008619B1 (ru)	2007-06-29
CN1553951A (zh)	2004-12-08
DE60123293D1 (de)	2006-11-02
NO20031999L (no)	2003-07-02
PT1404815E (pt)	2006-12-29
EE200300205A (xx)	2003-08-15
CZ20031165A3 (cs)	2003-10-15
JP4799804B2 (ja)	2011-10-26
US7560280B2 (en)	2009-07-14
UA81390C2 (en)	2008-01-10
JP2008179642A (ja)	2008-08-07
BG107770A (bg)	2004-02-27
HK1071771A1 (en)	2005-07-29
CA2426987C (en)	2013-06-11
CA2426987A1 (en)	2002-05-10
JP4805960B2 (ja)	2011-11-02
WO2002036751A2 (en)	2002-05-10
EP1404815B1 (en)	2006-09-20
WO2002036751A3 (en)	2004-01-08
JP2004521617A (ja)	2004-07-22
US20050142118A1 (en)	2005-06-30
EP1404815A2 (en)	2004-04-07
PL362293A1 (en)	2004-10-18
AU2002229533B2 (en)	2007-07-26
HUP0301600A3 (en)	2005-12-28
ATE340255T1 (de)	2006-10-15
AU2953302A (en)	2002-05-15
IL155608A0 (en)	2003-11-23
IL155608A (en)	2009-08-03
NO20031999D0 (no)	2003-05-02
CY1106287T1 (el)	2011-10-12
EA200300536A1 (ru)	2003-12-25
MXPA03003844A (es)	2004-10-15
US7556801B2 (en)	2009-07-07
DE60123293T2 (de)	2007-05-10
HUP0301600A2 (hu)	2003-10-28
DK1404815T3 (da)	2007-01-08
ES2272563T3 (es)	2007-05-01
US20090238803A1 (en)	2009-09-24
CN100480375C (zh)	2009-04-22
US20020164794A1 (en)	2002-11-07

Publication	Publication Date	Title
US7560280B2 (en)	2009-07-14	Human cord blood derived unrestricted somatic stem cells (USSC)
AU2002229533A1 (en)	2002-07-18	Human cord blood derived unrestricted somatic stem cells (ussc)
JP6483187B2 (ja)	2019-03-13	増強された幹細胞組成物
EP3107995B1 (en)	2019-10-30	Biophysically sorted osteoprogenitors from culture expanded bone marrow derived mesenchymal stromal cells (mscs)
Itescu et al.	2003	New directions in strategies using cell therapy for heart disease
CN108884441B (zh)	2022-05-06	集落形成培养基及其用途
KR20140143363A (ko)	2014-12-16	기질 줄기 세포
JP6545690B2 (ja)	2019-07-17	栄養膜基底層から由来した幹細胞及びそれを含む細胞治療剤
KR20170036105A (ko)	2017-03-31	치료학적 용도의 줄기 세포 조성물 및 줄기 세포의 제조 방법
Sonoyama et al.	2005	Skeletal stem cells in regenerative medicine
Calavul et al.	2023	The role of stem cell in plastic reconstructive and aesthetic surgery
Kögler et al.	2015	Cord Blood Content
DIFFERENTIATE et al.	2004	Final accepted version
Sivajothi	2016	Comparative properties of stromal cells and their role in tissue regeneration
Lindroos	2009	Characterization and optimization of in vitro culture conditions of adult stem cells for clinical cell therapy
Malagola	2013	Isolation and characterization of mesenchymal stromal cells from the canine liver
Itescu	0	Monitoring Stem Cell Research

Legal Events

Date	Code	Title	Description
2011-05-06	FC9A	Refused patent application